Cabrera-Marante Oscar, Pleguezuelo Daniel, Garcinuño Sara, Naranjo Laura, Díaz-Simón Raquel, Gil-Etayo Francisco Javier, Zafra Denis, Lozano-Morillo Fernando, Morillas Luis, Abad Magdalena, Villar Olga, Martínez-Salio Antonio, Lizarraga-Hurtado Tito Leoncio, Paz-Artal Estela, Serrano Antonio, Serrano Manuel
Immunology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Facultad HM de Ciencias de la Salud, Universidad Camilo José Cela, Villanueva de la Cañada, Madrid, Spain.
Front Immunol. 2025 Aug 1;16:1636171. doi: 10.3389/fimmu.2025.1636171. eCollection 2025.
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by thrombotic symptoms (venous, arterial, or small vessels) and/or gestational morbidity in patients carrying antiphospholipid antibodies (aPLs). Criteria aPLs include anti-cardiolipin antibodies, anti-beta 2 glycoprotein I (aB2GPI) antibodies of the IgG or IgM isotypes, and lupus anticoagulant (LA). However, there are aPLs that are associated with APS events but are not included in the criteria (extra-criteria). The aim of this study is to evaluate the prevalence and association of criteria and extra-criteria aPLs with APS clinical events.
A total of 838 patients with clinical manifestations of APS were studied. In total, 715 presented with vascular manifestations, and 130 presented with obstetric morbidity. We measured levels of criteria aPLs, and the extra-criteria aPLs determined were anti-phosphatidylserine/prothrombin (aPS/PT) of IgG and IgM isotypes and aB2GPI IgA.
Classic aPL, aPS/PT, and aB2GPI IgA positivity showed a significant and independent association with thrombosis (OR: 2.40, 2.36, and 2.53 respectively). IgA aB2GP1 was the only aPL significantly associated with the five types of thrombotic events (venous thrombosis, pulmonary embolism, stroke, acute myocardial infarction, and arterial thrombosis). Regarding obstetric APS, the most relevant antibodies were classic aPL of IgM isotype (OR: 36.04) and aPS/PT of both isotypes (OR: 4.4). The other aPL studied did not show association in multivariate analysis.
The degree of clinical association for each group of aPLs was different depending on the form of presentation (vascular or obstetric) and the presence or absence of autoimmune diseases. Moreover, a fair level of agreement between LA and aPS/PT positivity was found; therefore, aPS/PT should not be referred to as a surrogate marker of LA.
抗磷脂综合征(APS)是一种全身性自身免疫性疾病,其特征为携带抗磷脂抗体(aPL)的患者出现血栓形成症状(静脉、动脉或小血管)和/或妊娠并发症。标准aPL包括抗心磷脂抗体、IgG或IgM同种型的抗β2糖蛋白I(aB2GPI)抗体以及狼疮抗凝物(LA)。然而,存在一些与APS事件相关但未纳入标准的aPL(标准外)。本研究的目的是评估标准aPL和标准外aPL与APS临床事件的患病率及相关性。
共研究了838例有APS临床表现的患者。其中,715例有血管表现,130例有产科并发症。我们检测了标准aPL的水平,所确定的标准外aPL为IgG和IgM同种型的抗磷脂酰丝氨酸/凝血酶原(aPS/PT)以及aB2GPI IgA。
经典aPL、aPS/PT和aB2GPI IgA阳性与血栓形成呈显著独立相关(OR分别为:2.40、2.36和2.53)。IgA aB2GP1是唯一与五种血栓形成事件(静脉血栓形成、肺栓塞、中风、急性心肌梗死和动脉血栓形成)显著相关的aPL。关于产科APS,最相关的抗体是IgM同种型的经典aPL(OR:36.04)和两种同种型的aPS/PT(OR:4.4)。在多变量分析中,所研究的其他aPL未显示相关性。
每组aPL的临床关联程度因表现形式(血管性或产科性)以及自身免疫性疾病的有无而异。此外,发现LA和aPS/PT阳性之间有相当程度的一致性;因此,aPS/PT不应被视为LA的替代标志物。